MAD2L2 and lung carcinoma: In summary, our study showed that MAD2L2 rs746218 was significantly associated with platinum-based chemotherapy, and PFS and TNFRSF1A rs4149570 was significantly associated with OS time in patients with lung cancer treated with platinum-based chemotherapy.